Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03534622 · ClinicalTrials.gov registry record · Phase 1
Evaluate Safety and Pharmacokinetic To Assess Bronchopulmonary Disposition of Intravenous Delafloxacin in Healthy Adults
A Phase 1 study, sponsored by Melinta Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT03534622 is a Phase 1 study that has completed, run by Melinta Therapeutics. The registered enrollment target is 30 participants.
The verdict
NCT03534622, a Phase 1 study, has completed, sponsored by Melinta Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the steady-state intrapulmonary disposition of delafloxacin in healthy adult participants.
Interventions
- DRUG Delafloxacin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-04-30 |
| Est. Completion | 2018-07-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03534622
The ClinicalTrials.gov registry entry for NCT03534622 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Melinta Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Delafloxacin is the first listed.
NCT03534622 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03534622 about?
NCT03534622 is a clinical study titled "Evaluate Safety and Pharmacokinetic To Assess Bronchopulmonary Disposition of Intravenous Delafloxacin in Healthy Adults". The purpose of this study is to evaluate the steady-state intrapulmonary disposition of delafloxacin in healthy adult participants.
What is the current status of trial NCT03534622?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2018-04-30. Estimated completion is 2018-07-27.
What interventions are being tested in trial NCT03534622?
The interventions under investigation include: Delafloxacin (DRUG).
Who is sponsoring clinical trial NCT03534622?
This trial is sponsored by Melinta Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.